AstraZeneca gets FDA nod for rare blood disease therapy
2024-04-01
上市批准并购临床结果
The U.S. FDA has approved AstraZeneca's oral Factor D inhibitor as an add-on therapy to ravulizumab or eculizumab for a subset of adults with the rare blood disease, paroxysmal nocturnal hemoglobinuria.
Voydeya (danicopan) is approved as an add-on to the standard-of-care — AstraZeneca's C5 inhibitorsC5 inhibitors, Ultomiris (ravulizumab) or Soliris (eculizumab) — to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant extravascular hemolysis (EVH) while treated with a C5 inhibitor. For some patients, EVH, which is the destruction of red blood cells outside of the blood vessels, results in continued symptoms of anemia and may require blood transfusions.
AstraZeneca picked up danicopan in 2021 through its $39 billion mega buyout of Alexion after Alexion acquired the drug through its $930 million buyout of Achillion Pharmaceuticals in 2019.
Voydeya will go up against Novartis' Factor B inhibitor, branded Fabhalta, which was approved as the first oral monotherapy for the treatment of adults with PNH back in December. According to Novartis, Fabhalta addresses the unmet needs of patients being treated with AstraZeneca's Ultomiris or Soliris, including EVH. Fabhalta was tested against Ultomiris or Soliris in the open-label APPLY-PNH trial, where the drug proved superiority.
But, AstraZeneca's trial results for Voydeya suggest that a dual complement pathway inhibition at Factor D and C5 may be an optimal treatment approach for EVH patients.
The approval for AstraZeneca comes just days after the FDA approved a label expansion for Ultomiris, for the treatment of neuromyelitis optica spectrum disorder (NMOSD). First approved in 2018 as a treatment for PHN, Ultomiris has notched subsequent approvals in hemolytic uremic syndrome (a rare condition that leads to progressive kidney failure), generalized myasthenia gravis (a chronic autoimmune disorder), and now, neuromyelitis optica spectrum disorder.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。